Desmopressin: Clinical Therapeutic Agent

Desmopressin is used to control the symptoms of a certain type of diabetes insipidus (water diabetes; condition in which the body produces an abnormally large amount of urine). It is also used to control excessive thirst and the passage of an abnormally large amount of urine that may occur after a head injury or after certain types of surgery. This drug is also used to control bed-wetting. Desmopressin is in a class of medications called hormones. It works by replacing vasopressin, a hormone that is normally produced in the body to help balance the amount of water and salt.

Therapies for monosymptomatic nocturnal enuresis

Nocturnal enuresis (NE) is a common voiding dysfunction in children, characterized by intermittent and involuntary urination during sleep in those over 5 years of age [1]. In 7-year-old children, the prevalence of NE is 5 ~ 10%. Untreated NE rarely resolves spontaneously, and in some children, symptoms persist into adolescence and adulthood, significantly impacting mental health and quality of life. At present, the treatments for MNE mainly include drug therapies and behavioral interventions. Desmopressin is the first-line drug, alarm therapy is the first-line behavioral therapy, and anticholinergic agents (such as solifenacin, tolterodine, and oxybutynin) may be used in selected cases, especially when bladder dysfunction is suspected. Different treatment regimens have their own characteristics in terms of efficacy, relapse rate, and safety: desmopressin has a rapid onset of action, but the relapse rate is high and there is a risk of water intoxication; alarm therapy has a slow onset, and its efficacy depends on the child’s ability to wake up; anticholinergic agents may relieve urinary incontinence symptoms, but are often associated with adverse events (AEs) such as constipation and dry mouth. Recent studies have increasingly focused on combination therapy strategies, such as desmopressin combined with alarm therapy or anticholinergic agents. While several randomized controlled trials (RCTs) have compared different treatment regimens, the majority focus on comparing combination therapy with monotherapy.[1]

Treatment of MNE is influenced by various factors such as nocturnal polyuria, dysregulated antidiuretic hormone secretion, bladder dysfunction, and sleep–arousal disturbances, highlighting the heterogeneity of the condition and the need for individualized clinical assessment. Currently, the most commonly utilized first-line therapies are desmopressin and enuresis alarm; however, treatment response varies considerably among patients, and these approaches may be associated with suboptimal efficacy, relapse, or adherence issues in certain clinical contexts. Although current treatment methods for MNE in children include medications, behavioral interventions, and their combinations, high-quality evidence is still scarce. In our study, the efficacy and safety of multiple treatment strategies were compared through a network meta-analysis, and the results support the therapeutic advantages of desmopressin in combination with anticholinergic agents. In recent years, some small studies have begun to explore new therapeutic modalities such as beta-3 adrenergic receptor agonists, selective serotonin reuptake inhibitors, and transcutaneous sacral nerve stimulation; although these methods have some theoretical promise, their efficacy is still controversial. Among the combination therapies, desmopressin plus oxybutynin showed the most notable effect. The efficacy of this medicine monotherapy was comparable to that of alarm therapy. CINeMA assessment indicated that the certainty of evidence for CR comparisons was primarily rated as low to moderate.

Information of von Willebrand Disease

Dr. Erik von Willebrand first described von Willebrand disease (vWD) in 1926, though the von Willebrand factor protein (vWF) was not recognized as distinct from factor VIII until the 1970s. In the mid-1980s, the von Willebrand factor gene was cloned (vWF). vWF is a large multimeric glycoprotein synthesized in endothelial cells and megakaryocytes. In primary hemostasis, vWF binds to platelets and collagen to aid formation of the platelet plug via promotion of platelet adhesion and platelet aggregation at sites of vessel injury. Within secondary hemostasis, vWF also binds to and serves as a carrier for factor VIII (FVIII). Desmopressin is a synthetic analogue of vasopressin which stimulates release of vWF and FVIII from the endothelium and platelet granules. Guidelines suggest a trial to assess response prior to clinical use. They should not be used in those with type 3 vWD and are typically avoided in type 2B vWD due to enhanced platelet binding with release of dysfunctional vWF and worsened thrombocytopenia. Desmopressin can be administered intravenously, subcutaneously, or intranasally. Tachyphylaxis is frequently observed and thus use should be limited to a maximum of 3 days in a row. Regarding perioperative use, desmopressin is not recommended for major surgery, including surgical procedures that require precise bleed control such as those in a critical organ where small amounts of bleeding could have life-altering implications. The definition of what constitutes a major surgery for individuals with vWD requires further standardization.[2]

Plasma-derived and recombinant vWF concentrates are available with variable ratios of FVIII to vWF, including FVIII free options. Within the USA available plasma-derived vWF concentrates include Wilate, Alphanate, and Humate, while Vonvendi is the only recombinant product available. Vonvendi of note contains no FVIII. vWF concentrates are utilized to normalize vWF levels for patients with lackluster response to desmopressin, or who cannot otherwise tolerate desmopressin. They are also used for patients with significant hemorrhage, undergoing major surgeries, or surgeries in critical areas. Advantages to using vWF concentrates include tolerability and ability to titrate dosing based on degree of bleeding, type of surgery, baseline vWF levels, and response to therapy. Monitoring of vWF levels is recommended with repeat dosing. Disadvantages of vWF concentrates include higher relative costs and intravenous administration. Plasma-derived concentrates have added potential risk of pathogen transmission, though risk is minimal. With intravenous administration there is risk of infusion site reactions including paresthesia, pruritus, flushing, dysgeusia, chest discomfort, and tachycardia. Likewise, systemic antifibrinolytics are very effective for control and prevention of recurrent oral mucosal bleeding. Desmopressin or vWF concentrates can be used for refractory bleeding. Other supportive care aimed at minimizing dislodgement of formed clots should be emphasized including avoiding vigorous swishing, soft food diet, avoidance of straws, and application of extraoral ice packs.

A rare case report on diabetes insipidus

Diabetes insipidus (DI) is a debilitating disorder with a prevalence of 1 in 25,000. DI can present at any age with a similar prevalence in males and females. Diagnosis of DI is established by a two-stage dehydration test and a vasopressin test that differentially identifies between neurohormonal/central DI and nephrogenic DI. The treatment of DI depends upon its cause. A rare occurrence of nephrogenic diabetes insipidus (DI) following liver transplantation despite elevated plasma antidiuretic hormone levels and normal brain imaging findings is of interest. On the sixth day post-transplantation, the patient developed polyuria, a hallmark symptom of DI, prompts a comprehensive differential diagnosis. Desmopressin therapy was initiated, leading to rapid symptom resolution and full recovery. This case underscores the diagnostic challenges of DI in liver transplant recipients, particularly in differentiating between central and nephrogenic forms. Conventional diagnostic tests for DI, like water deprivation, are not preferred in patients receiving liver transplantation. Therefore, clinical assessment, biochemical markers, and imaging play a crucial role in diagnosis. The patient was successfully managed with desmopressin, thus emphasizing the importance of early recognition of symptoms and prompt initiation of treatment to prevent complications in liver transplantation patients to ensure optimal outcomes. Thus, we show the potential for rare post-transplant complications and the need for individualized diagnostic and therapeutic strategies.[3]

References

[1]Chen X, Zeng F, Tian N, Wang B. Efficacy and safety of first-line therapies and first-line-based combination therapies for monosymptomatic nocturnal enuresis in children: a network meta-analysis. Pediatr Nephrol. 2026 Mar 28. doi: 10.1007/s00467-026-07265-y. Epub ahead of print. PMID: 41902910.

[2]McGrath M, Weyand AC. Past, Present, and Future of von Willebrand Disease. Adv Ther. 2026 Mar 28. doi: 10.1007/s12325-026-03557-9. Epub ahead of print. PMID: 41902888.

[3]Shanmugam V, Shankar BA. A rare case report on diabetes insipidus following living donor liver transplantation in patient with alcoholic liver disease. Bioinformation. 2025 Dec 15;21(12):4939-4944. doi: 10.6026/973206300214939. PMID: 41907877; PMCID: PMC13018315.

You may like